Severe Renal Impairment Is Associated With Symptomatic Intracerebral Hemorrhage After Thrombolysis for Ischemic Stroke

Serdar Tütüncü, MD*; Annerose M. Ziegler, MD*; Jan F. Scheitz, MD; Torsten Slowinski, MD; Andrea Rocco, MD; Matthias Endres, MD; Christian H. Nolte, MD

Background and Purpose—Patients with renal impairment (RI) have an increased risk of both thrombotic and hemorrhagic events. We aimed to clarify whether RI increases the risk of intracerebral hemorrhage (ICH) after intravenous thrombolysis with recombinant tissue plasminogen activator.

Methods—Patients who received intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset were retrospectively analyzed. Creatinine levels on admission served to calculate glomerular filtration rate (GFR) to estimate RI according to International Classification of Diseases criteria. Effect of RI on symptomatic ICH (sICH) was assessed using dichotomized (GFR <90 and <30 mL/min) and continuous GFR (centered data to test for linear and centered and squared data to test for curvilinear association).

Results—Of the 740 patients included, 83% had any RI (GFR <90 mL/min) and 5% had severe RI (GFR <30 mL/mL); 4.6% experienced sICH. Univariate comparisons revealed higher prevalence of sICH in patients with severe RI (P<0.01) but not with any RI. GFR as a continuous variable (centered and squared) was also associated with sICH (P=0.02), but GFR on its own was not. Severe RI and GFR (centered and squared) remained independently associated with sICH in multiple regression analyses.

Conclusions—Severe RI (GFR <30 mL/min) is associated with sICH after intravenous thrombolysis with recombinant tissue plasminogen activator. The association is curvilinear. Severe RI must be taken into account when balancing the risk–benefit ratio of intravenous thrombolysis with recombinant tissue plasminogen activator.

Key Words: acute renal failure cerebral hemorrhage stroke thrombolytic therapy

Intravenous thrombolysis with recombinant tissue plasminogen activator (iv-tPA) is the only approved treatment for acute ischemic stroke.1 However, iv-tPA increases the risk of symptomatic intracranial hemorrhage (sICH).2 Recently, several risk scores have been proposed to assess the risk of sICH. These scores included age, sex, stroke severity quantified by the National Institutes of Health Stroke Scale (NIHSS), baseline blood sugar, early infarct signs,3 systolic blood pressure, history of hypertension, body weight, onset-to-treatment time (OTT), and pretreatment with antiplatelet drugs.4,5

Although renal impairment (RI) is common in patients with stroke, only a few studies investigated whether RI influences the risk of sICH. Patients with low glomerular filtration rate (GFR) are known to have endothelial and platelet dysfunction and are at risk for both thrombotic and hemorrhagic events.3,6 In this study, we investigated the association between RI and prevalence of sICH in patients with stroke receiving iv-tPA.

Study Population
All patients with stroke who received iv-tPA within 4.5 hours of symptom onset at our institution between January 2005 and August 2012 were included. Iv-tPA was administered according to European license. The register has been described in detail elsewhere.7 Serum creatinine levels (mmol/L) were measured for each patient on admission and on day 30.

Methods

The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.113.002859/-/DC1.

Correspondence to Serdar Tütüncü, MD, Department of Neurology, Charité, Universitätsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany. E-mail serdar.tuetuencue@charite.de © 2013 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.113.002859
ICH ≤36 hours and NIHSS worsening by ≥41 and radiologically detected type 1 and type 2 parenchymal hemorrhage (anyPH) within 36 hours after thrombolysis.

Statistical Analysis

For univariate analyses, 2-sided Pearson $\chi^2$ test was used. Continuous data were demonstrated as median and interquartile range, and Mann–Whitney $U$ test was applied for univariate analyses. Multivariable logistic stepwise regression analyses were used to test for independent associations with sICH and anyPH. Adjustment was made for variables associated with sICH or anyPH with $P<0.1$ in univariate comparisons, including cGFR, csGFR, and dichotomized GFR (severe RI). Sensitivity analyses included adjustment for variables suggested by the literature (history of hypertension, pretreatment with antiplatelet drugs, NIHSS, OTT, age, baseline blood sugar, and systolic blood pressure). Statistical analyses were performed using SPSS 19.

Results

The definition of the study population is shown in Figure 1. Among the 740 patients analyzed, 391 (53%) were men, median [interquartile range] age was 75 [66–83] years, median NIHSS on admission was 9 [5–16], median OTT was 120 [95–162.5] minutes, and median GFR was 66.95 [49.73–84.68] mL/min. sICH occurred in 34 (4.6%) and anyPH in 48 (6.5%) patients. RI based on GFR was absent in 124 (17%), mild in 336 (45%), moderate in 241 (33%), and severe in 39 (5%) patients.

Prevalence of both sICH and anyPH showed a steep increase in patients with severe RI compared with patients with no, mild, and moderate RI (Figure 2). Univariate comparison did not suggest higher sICH rates in patients with any RI. For baseline parameters see the online-only Data Supplement.

There was no significant linear association between cGFR and sICH or anyPH. But csGFR was indeed associated with sICH ($P=0.02$), suggesting a curvilinear association with an increase of sICH/anyPH in patients with low GFR. Additional variables suggesting association with sICH because of univariate comparisons with $P<0.1$ were older age, history of hypertension, and pretreatment with antiplatelet drugs.

Severe RI and csGFR remained independently associated with sICH after adjustment for these 3 variables (odds ratio $\text{severeRI} = 3.75$, 95% confidence interval [1.44–9.80]; odds ratio $\text{csGFR} = 1.56$, 95% confidence interval [1.13–2.15]; $P<0.01$ for both). Furthermore, severe RI and csGFR both remained independently associated with sICH after additionally adjusting for further variables suggested by the literature: NIHSS, baseline blood glucose, OTT, and systolic blood pressure (odds ratio $\text{severeRI} = 3.80$, 95% confidence interval [1.45–9.96]; odds ratio $\text{csGFR} = 1.61$, 95% confidence interval [1.16–2.23]; $P<0.01$ for both).

Discussion

This retrospective cohort study did not find an increased risk for sICH after iv-tPA in acute stroke patients with any RI. Nevertheless, our findings did suggest an increased risk for sICH in patients with severe RI (<30 mL/min). This finding was robust in 2 alternative multivariable regression analyses adjusted for various confounding factors and was supported by a third using continuous GFR, suggesting a curvilinear association with low GFR.

Patients with severe RI are indeed at an increased risk of any bleeding, including spontaneous sICH. This increased risk may partly be mediated by endothelial and platelet dysfunction. Previous data from observational studies are scarce and conflicting. Most of these studies did not show a significant association of RI with sICH. However, the studies lacked appropriate sample size and used different cutoffs for dichotomization. The largest previous study (N=578) originates from Japan, where rt-PA is administered at a lower dose (0.6 mg/kg BW). It demonstrated an increased risk for sICH in patients with moderate RI (GFR <60 mL/min). But Japanese patients might be more prone to sICH.
Severe RI (GFR <30 mL/min) is associated with sICH after iv-tPA. The association is curvilinear. Severe RI must be taken into account when balancing the risk–benefit ratio of iv-tPA. The association is curvilinear. Severe RI should be considered for future risk scores.

Sources of Funding
The research has received funding from the German Federal Ministry of Education and Research via the grant Center for Stroke Research Berlin (01 EO 0801).

Disclosures
Drs Tütüncü and Scheitz received a travel grant from Boehringer Ingelheim (BI). Dr Nolte reports receiving consulting lectures and travel grants from BI. Dr Endres has served on scientific advisory board for BI and received funding for travel and speaker honoraria from BI. The other authors report no conflicts.

References
Severe Renal Impairment Is Associated With Symptomatic Intracerebral Hemorrhage After Thrombolysis for Ischemic Stroke
Serdar Tütüncü, Annerose M. Ziegler, Jan F. Scheitz, Torsten Slowinski, Andrea Rocco, Matthias Endres and Christian H. Nolte

Stroke. 2013;44:3217-3219; originally published online September 3, 2013;
doi: 10.1161/STROKEAHA.113.002859
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/44/11/3217

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2013/09/03/STROKEAHA.113.002859.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
## Supplemental material

### Table 1: All baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>sICH yes</th>
<th>sICH no</th>
<th>p</th>
<th>anyPH (PH1+PH2) yes</th>
<th>anyPH (PH1+PH2) no</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, male % (n)</td>
<td>50% (17)</td>
<td>53% (374)</td>
<td>0.80</td>
<td>58% (28)</td>
<td>52% (363)</td>
<td>0.41</td>
</tr>
<tr>
<td>Age, Median [IQR]</td>
<td>79 [69-86]</td>
<td>74 [66-83]</td>
<td>0.05</td>
<td>77.5 [69-85]</td>
<td>74 [66-83]</td>
<td>0.14</td>
</tr>
<tr>
<td>NIHSS o.A.* ≥ 10, % (n)</td>
<td>53% (18)</td>
<td>50% (353)</td>
<td>0.72</td>
<td>58% (28)</td>
<td>49% (343)</td>
<td>0.23</td>
</tr>
<tr>
<td>Adm. from a nursing home, % (n)</td>
<td>14% (4)</td>
<td>12% (82)</td>
<td>0.74</td>
<td>10% (4)</td>
<td>12% (82)</td>
<td>0.63</td>
</tr>
<tr>
<td>Arterial Hypertension, % (n)</td>
<td>94% (32)</td>
<td>82% (585)</td>
<td>0.08</td>
<td>94% (45)</td>
<td>82% (572)</td>
<td>0.04</td>
</tr>
<tr>
<td>Diabetes Mellitus, % (n)</td>
<td>27% (9)</td>
<td>25% (180)</td>
<td>0.88</td>
<td>29% (14)</td>
<td>25% (175)</td>
<td>0.54</td>
</tr>
<tr>
<td>Hyperlipoproteinemia, % (n)</td>
<td>48% (15)</td>
<td>48% (331)</td>
<td>0.93</td>
<td>56% (25)</td>
<td>47% (321)</td>
<td>0.27</td>
</tr>
<tr>
<td>Atrial fibrillation, % (n)</td>
<td>47% (16)</td>
<td>40% (284)</td>
<td>0.42</td>
<td>48% (23)</td>
<td>40% (277)</td>
<td>0.27</td>
</tr>
<tr>
<td>Previous Stroke or TIA †, % (n)</td>
<td>15% (5)</td>
<td>24% (171)</td>
<td>0.21</td>
<td>21% (10)</td>
<td>24% (166)</td>
<td>0.63</td>
</tr>
<tr>
<td>Smoking, % (n)</td>
<td>15% (5)</td>
<td>22% (159)</td>
<td>0.29</td>
<td>15% (7)</td>
<td>23% (157)</td>
<td>0.18</td>
</tr>
<tr>
<td>OTT ‡ ≤ 180 Minutes, % (n)</td>
<td>91% (31)</td>
<td>84% (596)</td>
<td>0.26</td>
<td>88% (42)</td>
<td>84% (585)</td>
<td>0.53</td>
</tr>
<tr>
<td>BP (syst.) o.A. §, mmHg, Median [IQR]</td>
<td>160 [138-172]</td>
<td>150 [134-173]</td>
<td>0.45</td>
<td>158 [135-172]</td>
<td>150 [134-172]</td>
<td>0.57</td>
</tr>
<tr>
<td>Imaging by MRI, % (n)</td>
<td>18% (6)</td>
<td>29% (209)</td>
<td>0.14</td>
<td>23% (11)</td>
<td>29% (204)</td>
<td>0.35</td>
</tr>
<tr>
<td>Glucose mmol/l, Median [IQR]</td>
<td>7 [6-7.9]</td>
<td>6.6 [5.9-7.9]</td>
<td>0.30</td>
<td>7 [5.9-8]</td>
<td>6.6 [5.9-7.9]</td>
<td>0.19</td>
</tr>
<tr>
<td>INR, Median [IQR]</td>
<td>1.06 [1.01-1.12]</td>
<td>1.04 [0.99-1.11]</td>
<td>0.51</td>
<td>1.07 [1.01-1.13]</td>
<td>1.04 [0.99-1.11]</td>
<td>0.12</td>
</tr>
<tr>
<td>Pre-treatment antiplatelet drugs, % (n)</td>
<td>65% (22)</td>
<td>44% (307)</td>
<td>0.02</td>
<td>67% (32)</td>
<td>43% (297)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Pre-treatment OA † †, % (n)</td>
<td>3% (1)</td>
<td>3% (23)</td>
<td>0.91</td>
<td>6% (3)</td>
<td>3 (21)</td>
<td>0.23</td>
</tr>
<tr>
<td>Severe RI † †, % (n)</td>
<td>18% (6)</td>
<td>5% (33)</td>
<td>&lt;0.01</td>
<td>13% (6)</td>
<td>5% (33)</td>
<td>0.02</td>
</tr>
<tr>
<td>Any RI**, % (n)</td>
<td>85% (29)</td>
<td>83% (587)</td>
<td>0.74</td>
<td>88% (42)</td>
<td>83% (574)</td>
<td>0.42</td>
</tr>
</tbody>
</table>

* ) National Institutes of Health Stroke Scale - Score on admission, † ) Transient ischemic attack, ‡ ) Onset to treatment time, § ) Systolic blood pressure on admission, || ) Oral anticoagulants, # ) Severe renal impairment = GFR < 30ml/min, * * ) Any renal impairment = GFR < 90ml/min